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DNA methylation at IL32 in 
juvenile idiopathic arthritis
Braydon Meyer1, Raul A Chavez1,2, Jane E Munro3,4, Rachel C Chiaroni-Clarke1,2, 
Jonathan D Akikusa3,4, Roger C Allen3,4, Jeffrey M Craig5,2, Anne-Louise Ponsonby5,2, 
Richard Saffery6,2 & Justine A Ellis1,2
Juvenile idiopathic arthritis (JIA) is the most common autoimmune rheumatic disease of childhood. 
We recently showed that DNA methylation at the gene encoding the pro-inflammatory cytokine 
interleukin-32 (IL32) is reduced in JIA CD4+ T cells. To extend this finding, we measured IL32 
methylation in CD4+ T-cells from an additional sample of JIA cases and age- and sex-matched 
controls, and found a reduction in methylation associated with JIA consistent with the prior data 
(combined case-control dataset: 25.0% vs 37.7%, p = 0.0045). Further, JIA was associated with 
reduced IL32 methylation in CD8+ T cells (15.2% vs 25.5%, p = 0.034), suggesting disease-associated 
changes to a T cell precursor. Additionally, we measured regional SNPs, along with CD4+ T cell 
expression of total IL32, and the γ and β isoforms. Several SNPs were associated with methylation. 
Two SNPs were also associated with JIA, and we found evidence of interaction such that methylation 
was only associated with JIA in minor allele carriers (e.g. rs10431961 pinteraction = 0.011). Methylation 
at one measured CpG was inversely correlated with total IL32 expression (Spearman r = −0.73, 
p = 0.0009), but this was not a JIA-associated CpG. Overall, our data further confirms that reduced 
IL32 methylation is associated with JIA, and that SNPs play an interactive role.
Juvenile idiopathic arthritis (JIA) is the most common autoimmune rheumatic disease in children, affect-
ing approximately one per thousand of European descent, and causing significant disability1,2. JIA is 
considered to be a complex disease, and as such, risk is presumed to be determined by both genetic 
and environmental factors3. Recent work has identified a number of genetic risk loci, including HLA, 
PTPN22, and genes of the IL-2 pathway4,5. Specific environmental factors potentially contributing to risk 
remain largely uncharacterised; however, a role for environmental exposures is supported by numerous 
lines of evidence for other autoimmune diseases6.
Epigenetic modification, including DNA methylation, is widely believed to provide a mechanism 
through which environmental and genetic risk factors interact to promote disease7. Indeed, there is 
a large and rapidly-growing body of evidence for altered DNA methylation in individuals with vari-
ous autoimmune diseases, including rheumatoid arthritis (RA)8–11, systemic lupus erythematosus12–14, 
inflammatory bowel disease15–17 and type 1 diabetes18,19. We recently performed a pilot genome-scale 
analysis of peripheral blood CD4+ T cell DNA methylation in (predominantly oligoarticular course) 
JIA20. Among the genomic regions showing evidence of differential methylation in JIA cases relative to 
age- and sex-matched controls, was the regulatory region of the cytokine interleukin-32 gene (IL32). 
IL-32 promotes the production of a number of pro-inflammatory molecules, including tumour necrosis 
factor alpha (TNFα ) and interleukin 621–23, cytokines that are targeted in biologic therapies for JIA24, and 
is therefore a biologically plausible candidate gene for JIA pathogenesis.
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IL-32 has been implicated in a number of different biological pathways, including cell death, host 
defence, and immune function25,26. Several lines of evidence also suggest that IL-32 plays an important 
role in inflammatory arthritis (for review, see27). Shoda et al. showed that IL32 expression is prominent 
in synovial-infiltrated lymphocytes of RA patients, and overexpression has the capacity to exacerbate 
inflammatory arthritis in mice28. Park et al. showed that injection of IL-32 into mouse knee joints led 
to increased pro-inflammatory cytokine production, synovial inflammation and bone destruction29. 
Promotion of joint inflammation by IL-32 appears to be TNFα dependent, since IL-32 did not induce 
inflammation in TNFα -deficient mice30.
Six isoforms of IL-32 exist (γ , β , α , δ , ε , ζ ), as the result of mRNA splicing21,31,32. Heinhuis et al. 
observed that IL-32γ expression was significantly greater in RA compared to osteoarthritis (OA) syn-
ovial biopsies, and that in RA synovial tissues, IL-32γ expression was correlated with expression of 
pro-inflammatory cytokines including TNFα 33. Splicing of IL-32γ to IL-32β reduced pro-inflammatory 
potency, demonstrated by a lack of correlation of IL-32β with TNFα or IL-6, suggesting that splicing 
may serve as a mechanism to control inflammation33.
Given our prior evidence of reduced DNA methylation at IL32 in CD4+ T cells of individuals with 
JIA, and mounting evidence for a role for IL-32 in inflammatory arthritis, we sought to generate further 
evidence that IL32 plays a role in JIA. We investigated IL32 DNA methylation in circulating CD4+ T 
cells in a further JIA case-control sample, and in an additional immune cell subset, CD8+ T cells, con-
sidered the impact of single nucleotide polymorphisms (SNPs) on DNA methylation, and explored the 
relationship between CD4+ T cell IL32 methylation and IL32 expression.
Results
A 5’ region of IL32 is differentially methylated in JIA CD4+ T cells. We previously found evi-
dence for differential methylation of two CpG sites (designated CpG_10 and CpG_9; Fig.  1) in the 5’ 
region of IL32 in CD4+ T cells of children with JIA20. To confirm this association, we measured DNA 
methylation in the same genomic region (total of 10 CpG sites within nine assay units) in purified CD4+ 
T cells from a replication sample of 12 oligoarticular JIA cases and age- and sex-matched controls. The 
CD4+ IL32 methylation beta values for each replication sample at each measured CpG unit are given 
in Supplementary Table 5. As with our previous pilot data, we identified a significant reduction in mean 
methylation in JIA cases relative to controls (CpG_10: 10.3% (95% CI 5.8–14.9%) vs 19.0% (95% CI 
12.0–26.1%), t-test p = 0.032; CpG_9: 29.2% (95% CI 20.0–38.4%) vs 45.9% (95% CI 33.6–58.3%), t-test 
p = 0.028) (Fig. 2A,B). To maximise sample size for subsequent analyses, we combined all ‘original’ and 
‘replication’ sample methylation data (Fig. 2C,D). Overall, mean DNA methylation in JIA cases at both 
CpG_10 and CpG_9 was significantly reduced relative to controls in the combined dataset (CpG_10: 
10.7% (95% CI 7.9–13.7%) vs 17.1% (95% CI 12.3–21.9%), t test p = 0.025; CpG_9: 25.0% (95% CI 19.6–
30.3%) vs 37.7% (95% CI 30.6–44.8%), p = 0.0045). Logistic regression demonstrated that, for CpG_9, 
a 1% increase in methylation was associated with a 5% decrease in the risk of JIA (OR = 0.95, 95% CI 
0.92, 0.99, p = 0.008). CD4+ IL32 methylation levels at seven other analytic units (comprising 8 CpG 
sites) were not associated with JIA (Supplementary Table 5).
To maximise homogeneity amongst the cases, we reanalysed the association of JIA with IL32 methyla-
tion after removing the four polyarticular JIA cases from the ‘original’ sample set. Patterns of association 
were unchanged (data not shown).
Figure 1. Graphical representation of the gene structure of IL32, and location of CpGs and SNPs 
measured in this study. A. IL32 Gamma and Beta isoforms with regional SNPs annotated. B. Close-up of  
5’ gene region with measured CpGs annotated, other unmeasured CpGs in the region are shown in grey. 
Blue bars = exons. Grey bars = UTRs. Hg18 co-ordinates.
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A similar pattern of IL32 differential methylation is seen in JIA CD8+ T cells. In order to 
explore the potential cell specificity of the observed CD4+ T cell differential methylation in JIA, we 
measured IL32 methylation in CD8+ T cells isolated simultaneously with the CD4+ T cells in the 
‘replication’ case-control pairs. Resulting methylation values are given in Supplementary Table 5. For all 
CpGs measured, mean CD8+ T cell IL32 methylation was lower than in matched CD4+ T cells. As with 
CD4+ T cells, CD8+ T cell methylation at CpG_10 and CpG_9 was associated with JIA (CpG_10: 5.9% 
(95% CI 2.5–9.3%) vs 11.6% (95% CI 7.1–16.2%), t-test p = 0.037; CpG_9: 15.2% (95% CI 9.1–21.4%) vs 
25.5% (95% CI 17.7–33.3%), t-test p = 0.034). Logistic regression demonstrated that, for CpG_9, a 1% 
increase in methylation was marginally associated with a 10% decrease in the risk of being a JIA case 
(OR = 0.91, 95% CI 0.83, 1.00, p = 0.054). CD8+ IL32 methylation at other measured CpGs was not 
associated with JIA.
We measured the correlation of CpG methylation within and between CD4+ and CD8+ T cells. In 
general, there was a high level of correlation between CpG sites within each cell type (Supplementary 
Tables 6 and 7). CpG_9 and CpG_10 were highly correlated in both CD4+ T cells (Pearson r = 0.86, 
p < 0.0001) and CD8+ T cells (Pearson r = 0.84, p < 0.0001). When methylation levels were compared 
between cell types, CpG_1, CpG_3, CpG_8, CpG_9 and CpG_10 in CD4+ T cells were significantly 
correlated with their equivalent CpG in CD8+ T cells (Table 1).
SNPs in the IL32 gene region are associated with methylation. We found the genotypes of a 
number of SNPs in the IL32 region of chromosome 16 to be correlated with methylation at specific CpG 
sites. Table 2 shows the nine SNPs that were significantly associated with at least one CpG methylation 
level in at least one cell type. Methylation at CpG_10 and CpG_9 in CD4+ T cells appeared to be most 
commonly impacted by genotype, associated with six SNPs and four SNPs respectively. The SNP with 
the strongest overall evidence for association with IL32 methylation (high number of CpGs and low p 
value for association) was rs1554999. Figure 3 shows the correlation plots of rs1554999 with methylation 
at the three CpGs with which it is correlated in CD4+ T cells.
Figure 2. Methylation beta values in JIA cases and controls at the two significantly different IL32 CpG 
sites. A: CpG_10 in replication samples. B: CpG_9 in replication samples. C: CpG_10 in original and 
replication samples combined. D: CpG_9 in original and replication samples combined.
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CD4+ T cell IL32 methylation remains associated with JIA after taking into account the effect 
of SNPs. We noted that two SNPs found to be associated with IL32 methylation, rs10431961 and 
rs7188573, were also associated with JIA by logistic regression (rs10431961: OR = 2.74; 95% CI 1.23, 
6.12; p = 0.014; rs7188573: OR = 3.14; 95% CI 1.32, 7.49, p = 0.010). Given this, we considered them 
as confounders in the logistic regression model assessing the association between methylation and JIA. 
After adjusting for these two SNPs, CD4+ T cell CpG_10 methylation no longer remained associated 
with JIA (OR = 0.96, 95% CI 0.91, 1.01, p = 0.11). However, the association was still apparent for CpG_9 
(OR = 0.96, 95% CI 0.92, 0.99, p = 0.034). Again, these patterns of association were not materially altered 
by the removal of polyarticular JIA cases.
Evidence of interaction between genotype and IL32 methylation in JIA risk. We looked for 
evidence of interaction between SNPs rs10431961 and rs7188573 (main effect associations with JIA), 
and CD4+ DNA methylation at CpG_9. For rs10431961, we found that the association between JIA 
and CpG_9 methylation was present only in those with at least one minor allele (major allele homozy-
gote group: AOR = 0.99, 95% CI 0.94–1.04, p = 0.71; heterozygote plus minor allele homozygote group: 
AOR = 0.85, 95% CI 0.74–0.98, p = 0.023). There was statistically significant evidence of multiplicative 
interaction between CpG_9 and rs10431961 (AORint = 0.86, 95% CI 0.76–0.97, pint = 0.011). Similarly for 
rs7188573, we found that the association between JIA and CpG_9 was present only in those with at least 
one minor allele (major allele homozygote group: AOR = 0.98, 95% CI 0.93–1.03, p = 0.34; heterozygote 
plus minor allele homozygote group: AOR = 0.90, 95% CI 0.82–0.99, p = 0.028). Again, the test for inter-
action was statistically significant (AORint = 0.89, 95% CI 0.80–0.99, pint = 0.039). SNPs rs10431961 and 
rs7188573 are in moderate linkage disequilibrium in our sample (r2 = 0.76). However, conditioning the 
above interaction analyses on the opposite SNP did not materially alter the outcomes, suggesting that 
these two SNPs may be interacting independently with CD4+ T cell DNA methylation at CpG_9. The 
outcomes of these analyses were not altered by removal of polyarticular JIA cases.
Relationship between IL32 methylation and expression in CD4+ T cells. In order to directly 
ascertain the functional relevance of the observed differential methylation of IL32 in JIA, we measured 
expression of total IL32 (the sum of all transcript variants), IL32γ , and IL32β in CD4+ T cells from JIA 
cases and controls. Expression values were normalised to the housekeeping gene B2M; normalisation to 
an alternative housekeeping gene, RPLPO, did not materially alter the values (data not shown). Figure 4 
shows the distribution of relative expression values in JIA cases and controls. Supplementary Table 8 
provides individual-level relative expression values. There was a large range of values for each measure 
of IL32 expression in both cases and controls. Overall, we detected higher levels of expression of IL32β 
than IL32γ , consistent with prior evidence that IL32β is the more predominant IL32 gene product in T 
cells31. Regression analysis adjusting for age, sex, and blood time to processing demonstrated no associa-
tion between JIA and IL32 expression (total IL32: mean difference = 0.59, 95% CI − 1.91, 3.08; p = 0.63; 
IL32γ : mean difference = − 0.00045; 95% CI − 0.0051, 0.0042, p = 0.84; IL32β : mean difference = 0.060; 
95% CI − 0.093, 0.21; p = 0.43), although expression of total and β IL32 was higher in the cases, as might 
be expected with reduced case methylation. The lack of association between JIA and IL32 expression was 
unchanged on removal of the four polyarticular JIA cases from the dataset.
Table 1.  Correlations (Pearson r followed by p-value) between CD4+ and CD8+ T cells for each 
measured CpG (cases and controls combined).
www.nature.com/scientificreports/
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We next examined the correlations amongst total, γ and β isoforms in the CD4+ IL32 com-
bined case-control expression dataset. We observed correlation between total and γ IL32 relative 
expression (Spearman r = 0.45, p = 0.017) and total and β IL32 relative expression (Spearman 
r = 0.66, p = 0.0002). There was also a significant correlation between γ and β IL32 (Spearman 
r = 0.70, p = < 0.0001). Next, we looked for correlation between CD4+ IL32 methylation and 
expression amongst all available samples. There was evidence for a negative correlation between 
total IL32 relative expression and CpG_3 (Spearman r = − 0.73, p = 0.0009) (Fig. 5A) and IL32β 
relative expression and CpG_3 (Spearman r = − 0.48, p = 0.049) (Fig. 5B). In both cases the cor-
relation was in the biologically-predicted direction, that is, expression increased as CpG_3 meth-
ylation decreased. We used linear regression to adjust these associations for age, sex and time to 
blood sample processing and found that the association of total IL32 with CpG_3 methylation 
remained significant (β coefficient = − 0.071, 95% CI = − 0.14, − 0.0041, p = 0.039), as did the 
association between IL32β relative expression and CpG_3 methylation (β coefficient = − 0.0041, 
95%CI = − 0.0081, − 0.000045, p = 0.048. Methylation levels at no other CpGs were associated 
with IL32 expression.
In totality, these analyses do not provide compelling evidence of a direct link between IL32 expression 
level and 5’ IL32 methylation status in CD4+ T cells, or IL32 gene expression levels and JIA. However, 
the identification of specific associations in a subset of comparisons warrants further investigation.
Pearson correlation Linear regression*
SNP CpG
Cell 
type Pearson r p coefficient 95% CI p
rs3094471 10 CD4 0.31 0.014 5.57 1.37, 9.77 0.010
3 CD4 0.30 0.019 9.18 1.15, 17.21 0.026
rs10431961 10 CD4 − 0.29 0.020 − 5.29 − 9.49, − 1.09 0.015
9 CD4 − 0.40 0.0018 − 11.27 − 17.62, − 4.93 0.001
5 CD4 − 0.27 0.048 − 6.32 − 11.39, − 1.26 0.015
10 CD8 − 0.42 0.041 − 4.39 − 8.15, − 0.62 0.025
rs10438593 10 CD4 − 0.32 0.010 − 7.75 − 13.44, − 2.06 0.008
9 CD4 − 0.43 0.0008 − 16.61 − 24.73, − 8.48 < 0.001
rs7188573 10 CD4 − 0.32 0.012 − 6.17 − 10.64, − 1.71 0.008
9 CD4 − 0.44 0.0005 − 12.77 − 19.23, − 6.32 < 0.001
6.7 CD4 − 0.28 0.033 − 4.17 − 7.22, − 1.13 0.008
5 CD4 − 0.33 0.016 − 7.65 − 12.74, − 2.55 0.004
10 CD8 − 0.59 0.0025 − 8.02 − 11.83, − 4.21 < 0.001
9 CD8 − 0.40 0.059 − 10.20 − 18.87, − 1.53 0.024
rs28372698 10 CD4 − 0.27 0.030 − 4.21 − 8.05, − 0.36 0.032
3 CD4 − 0.76 < 0.0001 − 21.6 − 26.56, − 16.64 < 0.001
3 CD8 − 0.63 0.0011 − 17.21 − 26.20, − 8.21 0.001
rs1554999 10 CD4 0.54 < 0.0001 8.71 5.44, 11.99 < 0.001
9 CD4 0.60 < 0.0001 14.09 9.20, 18.99 < 0.001
3 CD4 0.54 < 0.0001 16.10 9.74, 22.46 < 0.001
9 CD8 0.43 0.040 8.52 1.71, 15.34 0.017
3 CD8 0.66 0.0004 21.78 13.28, 30.29 < 0.001
rs2239302 6.7 CD8 − 0.45 0.027 − 14.93 − 29.04, − 0.83 0.039
rs3789033 4 CD8 − 0.44 0.033 − 7.56 − 13.96, − 1.15 0.023
2 CD8 − 0.67 0.0008 − 4.20 − 7.17, − 1.23 0.008
rs2239316 4 CD8 − 0.44 0.034 − 6.84 − 12.65, − 1.03 0.023
2 CD8 − 0.63 0.0020 − 3.43 − 6.22, − 0.64 0.019
Table 2.  Significant associations between genotyped SNPs and IL32 CpG methylation in CD4+ and 
CD8+ T cells. *For linear regression, CpG methylation was converted to % methylation (β *100) for easier 
interpretation of the coefficient. The coefficient was adjusted for age and sex. The coefficient represents the 
change in % methylation for every additional minor allele of the SNP.
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SNPs in the IL32 gene region are not correlated with IL32 expression. We did not find any 
evidence of correlation between IL32 expression and genotyped SNPs (data not shown).
Overall relationships. The overall relationships of the IL32 genomic measures amongst themselves, 
and with JIA, are shown in Fig. 6. Taken together our results show that the association between reduced 
IL32 methylation and increased risk of JIA is robust, and that regional genotypes interact with IL32 5’ 
methylation to determine disease risk.
Discussion
We have confirmed the presence of reduced DNA methylation at CpGs in the 5’ region of IL32 in circu-
lating T cells in children with oligoarticular course JIA. Our previous data provided evidence, consistent 
in two case-control samples and across two assay platforms, of reduced IL32 methylation in JIA CD4+ 
T cells20. Here, we have shown, in a replication case-control sample, a statistically significant association 
between JIA and IL32 CpG methylation, with a direction of effect that is consistent with the prior work. 
When data from the original and replication samples (total 33 case-control pairs) was combined, the 
presence of association was further confirmed.
To complement these findings, we also measured DNA methylation at IL32 in CD8+ T cells and 
found that, in general, this cell type was less methylated than CD4+ T cells. This is consistent with prior 
evidence that IL32 is more highly expressed in CD8+ T cells34, and suggests a role for IL32 methylation 
in IL32 expression. Given that CD4+ (helper) and CD8+ (cytotoxic) T cells have functionally distinct 
roles in the immune system, the function of IL32 may differ between cell types. Indeed, there is evidence 
that both endogenous and exogenous agents stimulate IL32 expression in a number of different cell 
types, suggesting that IL32 might function in several aspects of immune defense via distinct pathways 
(for review see26). To our knowledge, however, no direct comparison of response of IL32 to such stimuli 
between CD4+ and CD8+ T cells has been performed.
There was, however, a significant correlation between CD4+ and CD8+ T cells, and methylation at 
the key site CpG_9 in CD8+ T cells was also associated with JIA. These data suggest two things. First, 
the correlation between the two cell types, along with the presence of disease association with both cell 
types, suggests the establishment of the JIA-related differential methylation patterns in a T cell precursor. 
Figure 3. Correlations between genotype at rs1554999 and IL32 β methylation values for CD4+ T cell 
CpGs (cases and controls combined). Only statistically significant correlations are shown. A. CD4 CpG_3, 
Pearson r = 0.54. B. CD4 CpG_9, Pearson r = 0.60. C. CD4 CpG_10, Pearson r = 0.54. SNP rs1554999 
genotype 0 = CC, 1 = CA, 2 = AA (minor allele homozygote).
www.nature.com/scientificreports/
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To understand how far back in the immune cell lineage this differential methylation pattern extends, fur-
ther work should examine IL32 methylation in a wider range of immune cell types. Our data concerning 
CD4+ and CD8+ T cells suggests that the ‘establishment’ of differential methylation extends at least 
back prior to maturation to ‘single positive’ T cells in the thymus35. This supports a role for differential 
IL32 methylation in disease causation, rather than disease consequence, which might more likely be 
reflected by changes in specific circulating immune cell subsets undertaking distinct functions in relation 
to disease processes. Correlation of disease-associated methylation changes across multiple immune cell 
types (T cells, B cells, monocytes) has also been reported in the autoimmune disease systemic lupus 
erythematosus (SLE)12. Such correlation amongst immune cells might provide the potential for DNA 
methylation to be used as a disease biomarker that is measureable in whole blood, simplifying the assay 
and thus increasing clinical utility.
By considering both regional SNP genotype and IL32 gene expression, we have also significantly 
extended our understanding of the relationships amongst these genomic measures, and how they impact 
the association between IL32 methylation and JIA. There is now considerable evidence that genetic 
sequence variants often impact methylation levels (methylation quantitative trait loci, or mQTLs), 
particularly early in life36,37. Data are also emerging implicating genotype-methylation interactions in 
phenotypic diversity apparent in conditions such as arthritis9. Recent data suggest the heritability of 
methylation profile per se to be around 20%38. A number of SNPs genotyped in this study were associ-
ated with IL32 methylation, and associations differed between CpG sites and between T cell types. Of 
note, rs1554999 was strongly associated with methylation at CpG_10 in CD4+ T cells, and at CpG_9 
and CpG_3 in both CD4+ and CD8+ T cells. This SNP is located in the 5’ region of IL32 (see Fig. 1), 
642 bp, 291 bp and 76 bp downstream of CpG_3, CpG_9 and CpG_10 respectively. This SNP has also 
been strongly associated with IL32 expression in peripheral blood (see Supplementary Table 3)39. This 
SNP in particular likely represents an IL32 cis methylation quantitative trait locus (mQTL). Two SNPs, 
rs10431961 and rs7188573, which lie 15 kb and 4 kb upstream of the IL32 transcription start site respec-
tively, were associated both with CD4+ T cell CpG_10 and CpG_9 methylation, and with JIA. Given 
that JIA is associated with reduced IL32 methylation, that the minor alleles of the above two SNPs are 
associated with reduced IL32 methylation, and that the minor alleles of the two SNPs are associated 
with an increased risk of JIA in our sample, these SNPs might explain the association between JIA and 
reduced IL32 CpG methylation. When these SNPs were included as covariates in the logistic regression 
model assessing association between JIA and IL32 methylation, evidence of association between JIA and 
Figure 4. Distribution of relative expression of A. total IL32, B. IL32γ and C. IL32β in CD4+ T cells from 
cases and controls. IL32 expression relative to B2M housekeeper gene expression.
www.nature.com/scientificreports/
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Figure 5. Correlation between IL32 relative expression and methylation in CD4+ T cells (cases and 
controls combined). A: Total IL32 and CpG_3, spearman r = − 0.73, p = 0.0009. B: IL32β and CpG_3, 
spearman r = − 0.48, p = 0.049.
Figure 6. Diagram of the relationships between each of the genomic measures and JIA. Solid lines 
indicate a correlation/association. Dashed lines indicate no correlation/association. Dot-dash lines indicate 
interaction such that the minor allele of the SNP potentiates the association between IL32 methylation and 
JIA. Asterisks indicate SNPs playing multiple roles in the causal pathway.
www.nature.com/scientificreports/
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CD4+ T cell CpG_9 methylation remained. Therefore, genotype at these SNPs does not entirely account 
for the lower methylation-higher disease risk relationship. Further, we found evidence that these SNPs 
interact with CpG_9 methylation in determining disease risk, with reduced methylation increasing risk 
of JIA only in those carrying at least one minor allele. CpG_9 methylation was not associated with JIA 
in major allele homozygotes. This pattern of association would not be expected if methylation acted only 
as an intermediary between the SNP and disease risk.
Regulation of gene expression is considered to be one of the major functions of DNA methylation40. 
In general, reduced methylation, particularly in CpG rich gene promoters, is associated with elevated 
gene expression, although recent evidence suggests that the opposite may be true for some CpG rich 
sequences, especially those within gene bodies40. We therefore assessed the relationship between expres-
sion and methylation of IL32 in CD4+ T cells. We found evidence of an inverse correlation between 
methylation at CpG_3 and expression of total IL32 and the β IL32 isoform. However, neither CpG_3 
methylation nor IL32 expression were observed to be associated with JIA.
There are a few potential explanations for the lack of correlation we observed between the JIA-associated 
differential IL32 methylation and gene expression. Firstly, other epigenetic mechanisms such as his-
tone modification and chromatin remodelling may be important in regulating gene expression at this 
locus, obscuring correlation between methylation and expression41. Secondly, methylation at CpG sites 
for which methylation is correlated with expression can lie many kilobases from the relevant gene. It is 
therefore possible that methylation at the CpGs found to be associated with JIA are more relevant to 
expression of nearby genes. Genes from both the TNF receptor and matrix metalloproteinase superfam-
ilies lie within 45 kb of CpG_9, and both gene families have been linked to inflammatory diseases42,43. 
Thirdly, If IL32 expression is more dynamic and sensitive to environmental influence than methylation, 
the impact of sample processing procedures may have served to obscure the methylation – gene expres-
sion relationship.
Strengths of our study include careful attention to clinical phenotype to maximise case homoge-
neity, exclusion of cases treated with methotrexate (a folate inhibitor) and other disease-modifying 
anti-rheumatic drugs, and consideration of multiple genomic factors and their interactions. A limi-
tation is the relatively small sample size, especially for association of genetic variants with outcomes. 
Additionally, treatment of cases with corticosteroids was not an exclusion criteria for this study. Although 
corticosteroids occur naturally in the body, it is possible that corticosteroid treatment (often injected 
directly to joints) may alter DNA methylation.
In summary, data presented here, in addition to data from our previous work20, provides strong 
evidence that DNA methylation of CpGs in the 5’ region of IL32 is reduced in oligoarticular JIA. The 
association was observed in two different immune cell subsets suggestive of a role in determining disease 
risk. Methylation in this region is impacted by genotype, but the methylation-disease association persists 
after the effect of genotype is taken into account. In addition, genotype and methylation were seen to 
interact, with the effect of methylation on JIA risk only evident in those carrying certain alleles. A lack 
of strong correlation between disease-associated IL32 methylation and IL32 expression suggests that 
other unmeasured factors may need to be considered to elucidate the relationship. Given that IL32 has 
an established role in promoting inflammatory arthritis in mouse models and adult rheumatoid arthritis, 
further work to understand the role of IL32 in JIA is well justified.
Materials and methods
Participant Recruitment and Selection. Cases and controls for the current study were drawn from 
the ChiLdhood Arthritis Risk factor Identification sTudY (CLARITY). A detailed description of the 
study has been published previously44,20. Briefly, cases were recruited from the Royal Children’s Hospital 
(RCH), Melbourne Australia. Cases were aged 18 years or under at recruitment, and were diagnosed with 
JIA and classified into clinical subtypes by a paediatric rheumatologist following International League of 
Associations for Rheumatology (ILAR) criteria45. Controls were healthy children aged 16 years or under 
attending the RCH day surgery unit for a minor surgical procedure. Peripheral blood mononuclear cells 
(PBMCs) were isolated using a ficoll procedure within 24 hours of blood collection, followed by storage 
in vapour-phase liquid nitrogen20. All study protocols were approved by the RCH Human Research 
Ethics Committee. Informed consent was obtained from all participants, and the research was carried 
out in accordance with the approved protocols.
Twenty-one CLARITY JIA cases (17 oligoarticular and four polyarticular) and 21 age and sex matched 
controls, for whom genome-scale and/or IL32 locus specific DNA methylation data was previously gener-
ated20, were included in the current study (‘original’ sample). The sample was augmented by the addition 
of twelve oligoarticular JIA cases (mean age 4.5 years, SD 3.5 years; 83.33% female) and twelve age and 
sex matched controls (‘replication’ sample). An additional unpaired case and two unpaired controls, 
for whom RNA was available, were included for the gene expression analyses (RNA-only sample). All 
selected cases were naive to methotrexate (MTX) and other biological disease modifying anti-rheumatic 
drugs at the time of blood collection. The characteristics of all original, replication, and RNA-only cases 
and controls are shown in Supplementary Table 1.
T Cell DNA/RNA Isolation. Total viable CD3+ CD4+ T cells, and CD3+ CD8+ T cells (replication 
samples only) were positively selected for from the PBMC population using flow cytometry (DAPI: Cat 
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ID D9542, Sigma Aldrich, St Louis, MO, USA; CD8-FITC: Cat ID 55536, CD3-APC Cat ID 340440, 
CD4-PE Cat ID 347327, Beckton Dickinson, San Jose, CA, USA). T cell purities were typically above 
98% for CD3+ CD4+ T cells and above 95% for CD3+ CD8+ following cell sorting. DNA was extracted 
using the Flexigene DNA extraction kit (Qiagen). Where CD4+ T cell numbers were sufficient, an ali-
quot of cells was used for RNA extraction using a standard Trizol extraction adapted from Chomczynski, 
et al.46, adjusting reagent volume to suit cell numbers. All RNA samples were DNase treated using the 
Ambion DNA Free kit (Life Technologies, Austin, TX USA).
Sequenom MassARRAY Epityper IL32 DNA Methylation analysis. DNA was bisulphite con-
verted using the MethylEasy Xceed kit (Human Genetic Signatures, Randwick, NSW Australia) accord-
ing to the manufacturer’s instructions. Measurement of methylation at IL32 was performed using two 
Sequenom MassARRAY Epityper assays as previously described20. Figure 1 shows the locations of CpGs 
in the 5’ region of IL32, indicating those measured by the assays.
Single nucleotide polymorphism (SNP) selection and Sequenom MassARRAY iPlex genotyp-
ing. SNPs in the region of IL32 were selected according to three criteria. First, we used CEU HapMap 
data47 and the tagger function in Haploview48 to identify tag-SNPs (defined as a proxy SNP representing 
a group of one or more SNPs amongst which r2 ≥ 0.8) in the region 3kb upstream to 10 kb downstream 
of the gene. A list of 7 SNPs representing variation at a total of 13 SNPs across the region was generated. 
Second, we identified any SNPs in the literature that had previously been examined for association with 
disease outcomes. Third, we used the Genevar eQTL database49 to identify SNPs correlated with IL32 
gene expression in either T cells, lymphoblastoid cells or fibroblasts from the Gencord study50. We used 
the Sequenom Assay Design Tool to design a single iPlex multiplex assay that incorporated as many of 
the identified SNPs as possible. The resulting iPlex assay included a total of 17 SNPs. Rationale for the 
inclusion of each SNP in the final assay is provided in Supplementary Table 2. SNPs in close proxim-
ity to, or within, IL32 are shown in Fig.  1. Correlations of SNPs with IL32 expression in the Genevar 
eQTL database are depicted in Supplementary Figure 1. SNPs also associated with peripheral blood 
IL32 expression in the Blood eQTL database39 are shown in Supplementary Table 3. SNPs were geno-
typed using the iPlex chemistry on the Sequenom MassARRAY according to manufacturer’s protocols. 
Primer sequences are provided in Supplementary Table 4. The Sequenom Typer program was used to 
call genotypes from raw data in a semi-automated fashion. Outliers on SNP cluster plots were visually 
inspected and calls rejected if unclear. DNA samples for which genotyping call rate was less than 90% 
were re-genotyped and subsequently discarded from analysis if call rate remained below 90%.
Quantitative Real Time PCR Expression Analysis. RNA samples were reverse transcribed to 
cDNA using the Tetro cDNA synthesis kit (Bioline, London, UK) as per the manufacturer’s instructions. 
Quantitative real time PCR was then used to quantify expression levels of total IL32 (all transcript variants), 
IL32γ and IL32β . Primers used to measure IL32γ and IL32β expression were as previously described23. 
Primers used to measure total IL32 expression were as follows: sense 5’-GATGGATTACGGTGCCGAG-3’; 
antisense 5’-CACAAAAGCTCTCCCCAGG-3’. IL32 expression was measured on the Applied Biosystems 
7300 Real Time PCR System. Each sample was run in triplicate and a cut-off Cycle Threshold (CT) 
value of ± 1 from the median value of all 3 data points was used to remove outlying replicate values. 
Replicates that passed this quality control were then used to calculate the mean CT value. The Δ CT 
analysis method was employed to calculate the relative difference in expression of IL32 and its iso-
forms to the endogenous control genes B2M (sense 5’-ATCATGGAGGTTTGAAGATGCC-3’; antisense 
5’- ACATGGAGACAGCACTCAAAGTAGA) and RPLP0 as per Dheda et al51.
Statistical Analysis. We used t-tests (mean comparison tests) and logistic regression to compare 
methylation β values between cases and controls. We used logistic regression to generate odds ratios 
(ORs) to gauge the degree of change in risk of JIA with changes in methylation levels. For this purpose 
we converted methylation β values to % methylation (β x 100) to facilitate OR interpretation. We calcu-
lated Pearson correlations amongst methylation data, and between methylation and SNP data. We used 
linear regression, adjusting for the potential covariates age and sex, to further assess the relationships 
between methylation and SNPs. We looked for evidence of interaction between SNPs and methylation 
in relation to JIA risk by use of a product term in logistic regression, adjusting for age and sex. SNP 
genotype groups were dichotomised for this purpose into major allele homozygotes, and heterozygotes 
plus minor allele homozygotes (dominant genetic model). For analyses incorporating expression data, we 
employed non-parametric analyses (Spearman correlation) alongside parametric analyses (linear regres-
sion adjusting for the potential covariates age, sex and blood sample time to processing). All analyses 
were undertaken using Stata v1352.
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